Bevacizumab and CCR2 Inhibitor Nanoparticles Induce Cytotoxicity-Mediated Apoptosis in Doxorubicin-Treated Hepatic and Non-Small Lung Cancer Cells

Document Type : Research Articles


1 Hormones Department, Medical Research Division, National Research Centre, Giza, Egypt.

2 Stem Cell Laboratory, Center of Excellence for Advanced Science, National Research Centre, Giza, Egypt.


Non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC) are very common in certain population
around the world. Despite the recent advances in their diagnosis and therapy, their prognosis remains poor due to the
development resistance to drug. Although doxorubicin (DOX) is considered to be one of the most anti-solid tumor
drugs, developed resistance is contributing to unsuccessful outcome. The rationale of the current study is to explore
the sensitizing capability of the DOX-treated cancer cells using the anticancer agents; bevacizumab (avastin; AV) and
CCR2 inhibitor (CR) in their free- and nano-formulations. Here, the average size, polydispersity index (PDI), zeta
potential, and entrpment effeciency (EE%) of the synthesized nanoparticles were measured. We investigated the effect
of these platforms on the proliferation, apoptosis, necrosis, nitric oxide (NO), malondialdehyde (MDA), and zinc levels
of human HCC (HepG2 and Huh-7) and NSCLC (A549) cancer cell lines. Glucose consumption rates using Huh-7
and A549 cancer cells were tested upon treatments. We demonstrated that AV and CR nano-treatments significantly
suppressed A549 cell viability and activated apoptosis by NO level elevation. We concluded that AVCR NP plus
DOX significantly induces A549 cytotoxicity-mediated apoptosis more than Huh-7 and HepG2 cells. This drug-drug
nano-combination induced Huh-7 cytotoxicity-mediated apoptosis more than HepG2 cells. In conclusion, AVCR NP
sensitized DOX-treated A549 and Huh-7 cells through reactive oxygen species (ROS)-stimulated apoptosis. Taken
together, our data suggested that the CR plus AV nano-platforms would be a potential personalized medicine-based
strategy for treating CCR2-positive NSCLC and HCC patients in the near future.


Main Subjects

Volume 20, Issue 7
July 2019
Pages 2225-2238
  • Receive Date: 28 October 2018
  • Revise Date: 14 February 2019
  • Accept Date: 22 July 2019
  • First Publish Date: 22 July 2019